Momenta Pharmaceuticals Announces Date of Third Quarter 2014 Financial Results Conference Call and Webcast
22 oct. 2014 08h00 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Oct. 22, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer
09 oct. 2014 16h15 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Oct. 9, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, announced...
Momenta Pharmaceuticals to Host 2014 R&D Day
02 oct. 2014 08h00 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Oct. 2, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals to Webcast Presentation at BioCentury's NewsMakers in the Biotech Industry Conference
17 sept. 2014 08h30 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Sept. 17, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Exercises Option to Acquire Novel Antibodies From AnaptysBio
08 sept. 2014 08h30 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Sept. 8, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Announces Abbreviated New Drug Application for Three-Times-a-Week Generic Copaxone Accepted for Review by FDA
28 août 2014 09h25 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Aug. 28, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals (Nasdaq:MNTA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Abbreviated New...
Momenta Pharmaceuticals Reports Second Quarter 2014 Financial Results
31 juil. 2014 08h00 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., July 31, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the second quarter ended June 30, 2014.
For the second...
Momenta Pharmaceuticals to Webcast Presentation at the Canaccord Genuity Growth Conference
30 juil. 2014 16h05 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., July 30, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Announces Date of Second Quarter 2014 Financial Results Conference Call and Webcast
15 juil. 2014 16h05 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., July 15, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
Momenta Pharmaceuticals to Webcast Presentation at the Wells Fargo Healthcare Conference
09 juin 2014 16h05 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., June 9, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...